BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) CEO Sells $7,044,470.76 in Stock

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) CEO John Oyler sold 27,802 shares of BeOne Medicines stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $253.38, for a total value of $7,044,470.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

John Oyler also recently made the following trade(s):

• On Monday, June 23rd, John Oyler sold 3,174 shares of BeOne Medicines stock. The stock was sold at an average price of $261.61, for a total value of $830,350.14.
• On Tuesday, June 17th, John Oyler sold 1,460 shares of BeOne Medicines stock. The shares were sold at an average price of $256.49, for a total value of $374,475.40.
• On Monday, June 16th, John Oyler sold 3,680 shares of BeOne Medicines stock. The stock was sold at an average price of $266.05, for a total value of $979,064.00.
• On Friday, June 6th, John Oyler sold 5,127 shares of BeOne Medicines stock. The shares were sold at an average price of $252.77, for a total value of $1,295,951.79.

BeOne Medicines Price Performance

NASDAQ ONC traded up $1.84 during trading hours on Monday, hitting $252.14. The company's stock had a trading volume of 105,997 shares, compared to its average volume of 432,422. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.71 and a current ratio of 1.96. The company has a market capitalization of $27.63 billion, a P/E ratio of -67.78 and a beta of 0.28. The stock has a 50 day moving average price of $247.15. BeOne Medicines Ltd. - Sponsored ADR has a 12 month low of $146.21 and a 12 month high of $287.88.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $1.93. The firm had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.12 billion. BeOne Medicines had a negative net margin of 9.40% and a negative return on equity of 7.55%. As a group, research analysts predict that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current fiscal year.

Institutional Trading of BeOne Medicines

Hedge funds have recently bought and sold shares of the company. Farther Finance Advisors LLC bought a new stake in shares of BeOne Medicines during the 2nd quarter valued at $39,000. Parallel Advisors LLC purchased a new position in BeOne Medicines during the second quarter valued at approximately $59,000. Avanza Fonder AB bought a new position in shares of BeOne Medicines in the second quarter worth approximately $199,000. Finally, Aaron Wealth Advisors LLC bought a new stake in shares of BeOne Medicines during the 2nd quarter valued at $200,000. Hedge funds and other institutional investors own 48.55% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on ONC. Guggenheim upped their price objective on shares of BeOne Medicines from $348.00 to $350.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. JPMorgan Chase & Co. boosted their price target on BeOne Medicines from $317.00 to $321.00 and gave the stock an "overweight" rating in a research report on Friday, June 27th. Morgan Stanley raised their price objective on BeOne Medicines from $313.00 to $330.00 and gave the company an "overweight" rating in a research report on Friday, June 27th. TD Securities reiterated a "buy" rating and set a $334.00 price objective on shares of BeOne Medicines in a research note on Thursday, April 24th. Finally, Royal Bank Of Canada raised BeOne Medicines from an "outperform" rating to a "moderate buy" rating and set a $311.00 target price on the stock in a research note on Friday, June 27th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, BeOne Medicines currently has an average rating of "Moderate Buy" and a consensus price target of $320.67.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.